National Institutes of Health

Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Tiziana Life Sciences is a clinical-stage biotechnology company based in the United Kingdom, dedicated to the discovery and development of innovative therapies targeting diseases in oncology and immunology. The company's product pipeline features Foralumab, a human anti-CD3 monoclonal antibody aimed at treating various autoimmune and inflammatory conditions, including graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently in phase II clinical trials for epithelial thymic carcinoma and has potential applications in hepatocellular carcinoma. Additionally, Tiziana develops Anti IL-6r, a monoclonal antibody for treating severe respiratory symptoms in hospitalized COVID-19 patients, and StemPrintER, a multi-gene assay designed for patients with specific types of breast cancer. Founded in 2013, Tiziana Life Sciences operates with a focus on advancing transformative therapies for challenging medical conditions.

Evoq Therapeutics is a company specializing in cancer immunotherapy and the treatment of autoimmune diseases. It employs a proprietary technology platform that features a NanoDisc, designed to deliver disease-specific immune modulators effectively. This innovative approach aims to restore immune tolerance, allowing the body to better manage conditions such as celiac disease, type one diabetes, lupus, pemphigus, Graves' disease, and rheumatoid arthritis. By targeting these diseases through its novel nanodisc-based therapy, Evoq Therapeutics seeks to improve the lives of individuals affected by autoimmune disorders and enhance the overall efficacy of treatment strategies in various pre-clinical models.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.

Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.

Selsym Biotech is a biotechnology company focused on developing innovative therapies aimed at controlling bleeding in trauma and surgical situations. The company's flagship product, Hemostatic Healing Hydrogels (H3), offers a novel solution to address critical challenges in hemorrhage control, particularly in light of ongoing platelet supply shortages and limitations related to shelf life. By providing effective platelet-mimetic therapies, Selsym Biotech seeks to revolutionize the management of uncontrolled bleeding, enhancing outcomes for patients in emergency and surgical settings.

Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.

Perspective Therapeutics is a medical technology and radiopharmaceutical company focused on innovative cancer treatment solutions. The company employs a proprietary technology that uses the alpha-emitting isotope 212Pb combined with specialized targeting peptides to deliver targeted radiation directly to cancer cells. This approach aims to enhance the effectiveness of treatments while minimizing side effects, reflecting the company's commitment to personalized and precise medicine in addressing patients' medical needs.

AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.

Hillhurst has created technology that allows low-dose carbon monoxide to be used therapeutically (CO). Their medicines that arise target a protective cellular metabolic system of heme oxygenase, that is hypothesized to reduce inflammatory processes, prevent cell death, and stop hemoglobin polymerization in sickle cell disease. Despite overwhelming evidence of CO's potential efficacy as a therapy, it has not been commercially feasible to dose carbon monoxide. The methods of administration that have been tried, such as breathing CO and CO bound to a carrier like co releasing molecules/CORMS and CO prodrugs, have significant drawbacks. These hurdles for inhaled co include caregiver inhalation exposure due to the need for pressurized co gas cylinders and imprecise dosing.

Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, that specializes in developing innovative therapeutics for neurodegenerative diseases and other conditions with unmet medical needs. The company has created a novel drug platform known as Clean-Surface Nanosuspension, which enables the production of clean-surface nanocrystal medicines. This technology supports a pipeline of new drug candidates, particularly targeting demyelinating disorders and oncology. Founded in 2012, Clene Nanomedicine aims to advance treatment options through its unique approach to drug development.

Integral Molecular, Inc. is a biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of innovative technologies to aid drug discovery for diseases such as cancer, HIV, and arthritis. The company offers the Lipoparticle technology, which facilitates the identification and optimization of drug candidates targeting integral membrane proteins. With over 20 years of experience in the field, Integral Molecular has supported more than 400 companies in their research efforts, medication discovery, and vaccine development. Its products play a crucial role throughout the drug discovery process, particularly in the development of antibodies and chemical compounds targeting challenging protein targets.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

South Rampart Pharma is a clinical-stage life science company dedicated to developing safe and effective pain relief alternatives. The company focuses on synthesizing and characterizing new non-opioid and non-liver toxic molecules that target pain signaling pathways in the brain's periaqueductal grey (PAG) region. Its lead candidate, SRP-001, has received U.S. FDA Fast Track designation for acute pain treatment. This candidate aims to influence pain-related genes through various biological pathways, including endocannabinoid signaling and mechanical nociception, providing a promising solution to mitigate the risks associated with traditional pain medications, particularly their potential for abuse.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

The University of Texas MD Anderson Cancer Center is a leading institution dedicated exclusively to cancer patient care, research, education, and prevention. Located in the Texas Medical Center in Houston, Texas, it was established as one of the original three comprehensive cancer centers under the National Cancer Act of 1971. MD Anderson serves as both a degree-granting academic institution and a specialized cancer treatment facility. It is affiliated with two prominent medical schools: The University of Texas Medical School at Houston and Baylor College of Medicine. Renowned for its exceptional cancer care, MD Anderson has consistently ranked among the top cancer hospitals in the United States, earning the No. 1 position in U.S. News & World Report's "Best Hospitals" survey for ten of the past twelve years. The center is widely recognized for its commitment to advancing cancer treatment and improving patient outcomes.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

Shirley Ryan AbilityLab is a translational research hospital. Their services include spinal cord injury recovery, brain injury recovery, COVID recovery, pediatric and adolescent rehabilitation, nursing, cancer rehabilitation, limb loss and impairment, and pain management.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Montefiore Health System offers advanced specialty programs, cardiology, and cardiac surgery. They provide cancer care, children’s health, tissue, and organ transplantation. Their services include women’s health, surgery, and surgical subspecialties. If anyone wants to contact them please contact them via phone call or email.

Dignify Therapeutics LLC is a drug development company based in Durham, North Carolina, that focuses on creating innovative pharmaceutical agents aimed at restoring voluntary control of bladder and bowel functions in patients with spinal cord injuries, spina bifida, multiple sclerosis, and other neurological conditions. Founded in 2013, the company combines novel drug therapies with advanced drug delivery technologies to enhance the quality of life for individuals affected by these disorders. By targeting the specific needs of this patient population, Dignify Therapeutics aims to redefine treatment options and provide effective solutions that enable patients to regain dignity in their excretory functions.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Cellular Logistics, Inc. is a biotechnology company founded in 2016 and based in Madison, Wisconsin. The company specializes in developing an acellular biomaterial that serves as a stand-alone therapeutic for cardiac and tissue vascularization applications. This innovative biomaterial aims to significantly enhance cell survival rates and retention in regenerative medicine therapeutics. It also functions as a delivery mechanism for these therapies, improving post-injection cell retention and ultimately benefiting patients undergoing regenerative treatments.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

Whitman-Walker Health provides health and wellness services. They provide HIV, prep, pep, medical and community care, insurance navigation services, gender affirming care and services, youth and family support, legal services, dental health, and behavorial health services.

We are a women's owned startup focusing on new therapeutic approaches to gynecological conditions. Our primary focus is endometriosis. We approach endometriosis with a holistic view and our therapies focus on the stress system rather that on the reproductive system.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

iQure Pharma is a global biotech company dedicated to developing innovative therapeutics for neurodegenerative diseases, particularly focusing on epilepsy. Founded by entrepreneurs and former pharmaceutical managers, the company aims to address unmet medical needs by creating new chemical entities with unique modes of action. This approach allows for the exploration of novel medical therapies, including options for patients who are resistant to existing treatments. By concentrating on these challenging conditions, iQure Pharma seeks to improve outcomes for individuals affected by epilepsy and other related disorders.

Pantherics is a new type of therapy based on modulation of peripheral GABAA receptors.

Immuto Scientific is a biotechnology services company that specializes in providing analytical insights to pharmaceutical firms involved in drug discovery. The company has developed a protein footprinting technology that automates complex protein analysis, significantly enhancing the efficiency of the drug development process for protein therapeutics. This technology offers a faster alternative to traditional methods for protein structure analysis, allowing drug developers to determine protein structures more quickly and effectively, thereby streamlining the overall drug discovery process.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Eliaz Therapeutics has developed a patented medical device that selectively removes galectin-3 from human blood, addressing currently untreatable life-threatening diseases. This device targets galectin-3, a protein associated with conditions such as diabetes, chronic kidney disease, organ fibrosis, and cancer. By employing a single-use apheresis column that utilizes a proprietary capturing molecule, the device effectively eliminates both bound and free galectin-3 from circulation. This innovative approach offers a less invasive treatment option with fewer side effects compared to traditional therapies, enabling physicians to provide effective care for patients suffering from acute kidney injury, sepsis, and other inflammatory and fibrotic diseases. The device is designed for easy integration into existing hospital practices, enhancing its potential for widespread adoption.

Reliant Glycosciences is a biotechnology company focused on developing diagnostic and prognostic tools for patients with IgA nephropathy.

Immunicom is redefining the limits of immunotherapy through the development of innovative, non-pharmaceutical treatment approaches for cancer, inflammatory diseases, and autoimmune diseases.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

NovoMedix has developed novel orally available small molecules with wide therapeutic windows to treat fibrotic disorders. While these molecules have shown remarkable efficacy in animal models of fibrosis, some of them have unique properties for the treatment of cancer. These first-in-class small molecules co-target pathways that provide cardioprotective and synergistic anti-tumor effects with standard-of-care chemotherapies for the treatment of triple negative breast cancer (TNBC). There is a dose-dependent delayed and progressive cardiomyopathy often observed years after cessation of treatment of breast cancer patients anthracyclines such as doxorubicin (Adriamycin). As a result, the leading cause of death in breast cancer survivors is cardiovascular disease, often caused by the same treatments that once saved their lives. NovoMedix compounds have synergistic effects with chemotherapies on cancer cells, potentially enhancing patient response while significantly minimizing cardiotoxicity, ultimately improving long-term survival by reducing mortality due to heart failure. The goal is to initiate IND enabling studies with the lead candidate and to deliver this novel and safe therapy to TNBC patients as soon as possible.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Mi-Helper helps to develop a non-drug remedy for migraine and mood issues.

Delpor, Inc. is engaged in the development of innovative drug delivery technologies that facilitate the sustained or pattern-specific release of proteins, peptides, and small molecules via a small non-mechanical subcutaneous implant. The company offers several technologies, including Prozor, which delivers antipsychotics and other small molecule drugs, and NANOPOR, designed for sustained release through specialized membrane architecture. Additionally, Delpor has developed the Delos PUMP, a self-contained device that allows for the pulsed delivery of medications at programmed intervals, benefiting treatments such as hormones for fertility, diabetes management, and pain relief. Founded in 2009 and located in San Francisco, California, Delpor aims to enhance medication adherence and patient convenience by providing an alternative to frequent injections through its implantable solutions.

4E Therapeutics is focused on developing innovative therapies for chronic pain disorders, particularly neuropathic pain, which represents a significant unmet medical need. The company specializes in creating orally bioavailable MNK inhibitors that exhibit enhanced tissue-specificity and pharmacokinetic profiles. These compounds are designed to effectively target and regulate the activity of pain-sensing neurons in the peripheral nervous system. In addition to neuropathic pain, 4E Therapeutics is also engaged in the discovery and development of treatments for migraine and acute pain, leveraging their expertise in analgesic activity demonstrated through multiple animal pain models.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.

Benten Technologies is a social impact company dedicated to democratizing healthcare. The organization has secured approximately $9 million in non-dilutive funding to develop a pipeline of digital therapeutics aimed at making healthcare services more accessible. In addition to its healthcare initiatives, Benten Technologies also provides technology consulting services, which encompass application development, management consulting, quality assurance, and research and development. By leveraging proven system integration methodologies and expertise, the company enables organizations to deliver effective, value-driven business solutions.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Praxis Biosresearch is a privately-held biopharmaceutical company focused on the discovery and development of novel prodrug stimulants for treatment of a range of chronic neuropsychiatric and neurodegenerative disorders. Their lead development candidate prodrug PRX-P4-003 is designed to offer the proven therapeutic benefits of currently marketed stimulants while hindering potential for intravenous abuse.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

HDT Bio is a clinical-stage biotechnology company focused on developing RNA vaccines and therapeutics to combat infectious diseases and cancer. Utilizing its innovative LION formulation technology, the company creates ribonucleic acid-based products that enhance the delivery and stability of nucleic acids through various administration routes. HDT Bio’s offerings include self-amplifying RNA vaccines and innate immune agonist therapeutics, which aim to activate innate immunity, amplify adaptive immune responses, and disrupt tumor tight junctions. The company's mission is to advance immunotherapy technologies in a cost-effective manner, addressing critical healthcare needs in both developed and low- to middle-income countries, particularly in the fight against some of the world's most dangerous infectious diseases.

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative treatments and diagnostic tools for nervous system disorders, particularly Alzheimer's disease. The company's lead therapeutic candidate, simufilam, is undergoing Phase 3 clinical trials to assess its efficacy in treating Alzheimer's disease dementia. Additionally, Cassava is advancing SavaDx, a blood-based diagnostic aimed at detecting Alzheimer's disease early, potentially years before symptoms manifest. Founded in 1998 and originally known as Pain Therapeutics, Inc., Cassava Sciences has shifted its focus to neuroscience, leveraging scientific insights to address the complex challenges associated with neurological conditions.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology developed by Professor John Rose at Yale University School of Medicine. We are dedicated to creating recombinant and replication proficient-virus like vesicle (VLV)-based vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

MRIMath specializes in medical imaging technology aimed at improving cancer diagnosis and treatment. The company develops solutions that assist oncologists and surgeons in identifying tumors and assessing treatment responses, thereby enhancing patient outcomes in oncology. MRIMath's innovative approach incorporates an interactive human-AI interface that offers a reliable and cost-effective tool for medical practitioners to monitor brain tumor growth. Beyond its imaging technology, MRIMath also provides hospital care, medical device services, and AI consulting, along with AI-powered software designed to streamline healthcare processes.

PhagePro is an early-stage biotechnology therapeutics company focused on developing bacteriophage-based products aimed at preventing bacterial infections, particularly in vulnerable communities worldwide. By offering innovative alternatives for disease prevention, PhagePro seeks to control outbreaks in both clinical and community settings. Its products play a crucial role in addressing public health challenges, helping to prevent fatal diseases such as cholera and enhancing overall health outcomes.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Abterra Biosciences specializes in antibody discovery and sequencing services aimed at enhancing therapeutic antibody development. The company utilizes advanced technologies, including next-generation sequencing, mass spectrometry, and machine learning, to analyze antibody responses and rapidly identify high-affinity therapeutic antibodies. Its innovative platform, Alicanto, streamlines the discovery process by identifying target-specific antibodies directly from serum, eliminating the need for traditional and time-consuming methods such as cell selection and cloning. By combining the expertise of data scientists and biologists, Abterra Biosciences aims to provide healthcare researchers with new insights and efficient solutions in the field of antibody therapeutics.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Abterra Biosciences specializes in antibody discovery and sequencing services aimed at enhancing therapeutic antibody development. The company utilizes advanced technologies, including next-generation sequencing, mass spectrometry, and machine learning, to analyze antibody responses and rapidly identify high-affinity therapeutic antibodies. Its innovative platform, Alicanto, streamlines the discovery process by identifying target-specific antibodies directly from serum, eliminating the need for traditional and time-consuming methods such as cell selection and cloning. By combining the expertise of data scientists and biologists, Abterra Biosciences aims to provide healthcare researchers with new insights and efficient solutions in the field of antibody therapeutics.

Coral Genomics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company specializes in optimizing drug development and deployment through the use of genomic data derived from patients. Coral Genomics focuses on creating new clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly those with autoimmune conditions such as Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, the company has identified a distinct population of non-responder patients and collaborates with drug developers to address their unmet medical needs.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Ocuphire Pharma is a clinical-stage biopharmaceutical company based in Farmington Hills, Michigan, that specializes in developing and commercializing therapies for various ophthalmic disorders. The company’s lead product candidate is Nyxol, a once-daily preservative-free eye drop formulation designed to treat conditions such as dim light vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Nyxol is currently in late-stage clinical development, supported by extensive safety and efficacy data from previous trials. Additionally, Ocuphire is advancing APX3330, an oral tablet aimed at addressing diabetic retinopathy and diabetic macular edema, which is in Phase 2 clinical development. The company is also exploring opportunities to acquire further ophthalmic assets and seeks strategic partnerships for global commercialization of its products.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurological disorders. The company specializes in chemogenetic technology, which allows for precise modulation of neuronal activity through gene therapy. By using viral vectors, Coda Biotherapeutics introduces engineered neurotransmitter receptors into specific neuronal populations. These receptors are designed to respond to a proprietary small molecule, enabling targeted control of neuronal functions. This approach aims to effectively treat conditions such as neuropathic pain, epilepsy, and movement disorders, offering a potential advancement over traditional therapies. Founded in 2014, Coda Biotherapeutics is headquartered in San Francisco, California.

Armis Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing late-stage clinical products and antimicrobial therapies. Based in Fort Collins, Colorado, the company specializes in non-systemic anti-infective therapeutics aimed at combatting antibiotic resistance and healthcare-associated infections. Its product offerings include Ximycin, a patented localized antimicrobial therapy that provides broad-spectrum coverage against polymicrobial infections at surgical sites, and Veriox, a proprietary platform utilizing peracid technology to treat infections while also promoting positive tissue effects. Armis Biopharma serves various markets, including wound care, orthopedics, and dermatology, and addresses the growing challenges posed by resistant pathogens and chemical/biological threats. The company was incorporated in 1997 and continues to expand its innovative pipeline to meet critical healthcare needs.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Benten Technologies is a social impact company dedicated to democratizing healthcare. The organization has secured approximately $9 million in non-dilutive funding to develop a pipeline of digital therapeutics aimed at making healthcare services more accessible. In addition to its healthcare initiatives, Benten Technologies also provides technology consulting services, which encompass application development, management consulting, quality assurance, and research and development. By leveraging proven system integration methodologies and expertise, the company enables organizations to deliver effective, value-driven business solutions.

Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.

Aqualung Therapeutics (Aqualung Therapeutics Corporation) leadership are experienced academic leaders, entrepreneurs and translational scientists with expertise in Precision Medicine, who are exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders. As an organization they are committed to finding novel targets in the treatment of respiratory diseases. Their team is highly skilled at clinical development and they are working collaboratively with the FDA to ensure both acute and chronic respiratory diseases that have significant unmet medical need receive priority review.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Plex Pharmaceuticals is a drug discovery company dedicated to transforming academic research into effective treatments for unmet medical needs, particularly in the realm of neurodegenerative disorders. The company focuses on developing modulators of heat shock proteins and FK506 Binding Protein to address conditions caused by protein misfolding, including amyotrophic lateral sclerosis (ALS) and Parkinson's disease, as well as cataracts. In addition to its work in neurodegeneration, Plex is also advancing antiviral drug programs targeting diseases such as Dengue, West Nile, and Zika. Through its innovative approach, Plex aims to enhance the quality of life for patients facing complex, degenerative diseases.

Aqualung Therapeutics (Aqualung Therapeutics Corporation) leadership are experienced academic leaders, entrepreneurs and translational scientists with expertise in Precision Medicine, who are exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders. As an organization they are committed to finding novel targets in the treatment of respiratory diseases. Their team is highly skilled at clinical development and they are working collaboratively with the FDA to ensure both acute and chronic respiratory diseases that have significant unmet medical need receive priority review.

NanoScope Technologies was founded in 2009 with an objective to develop new methods and devices for scientific, industrial and biomedical applications. Nanoscope has developed a range of biomedical technologies which include diagnostics and therapeutic devices and molecules. These have already generated interest from several clinicians, industries and leaders. We strive to translate the technology to market and bedside.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative treatments and diagnostic tools for nervous system disorders, particularly Alzheimer's disease. The company's lead therapeutic candidate, simufilam, is undergoing Phase 3 clinical trials to assess its efficacy in treating Alzheimer's disease dementia. Additionally, Cassava is advancing SavaDx, a blood-based diagnostic aimed at detecting Alzheimer's disease early, potentially years before symptoms manifest. Founded in 1998 and originally known as Pain Therapeutics, Inc., Cassava Sciences has shifted its focus to neuroscience, leveraging scientific insights to address the complex challenges associated with neurological conditions.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Lohocla is a research and development company that is at the forefront of discovery bioscience center photoof medications for chronic pain, addictive and other mental health and neurological disorders. Lohocla is also unique in its dedication to developing biological markers (diagnostics) that aid the physician in properly allocating Lohocla-developed medications to the appropriate patients. The tenets of personalized medicine drive the company’s research efforts.

Globin Solutions, Inc. is a pre-clinical stage biopharmaceutical company that is committed to researching and developing a rapidly acting antidote for carbon monoxide poisoning, the most common human poisoning. Globin intends to aggressively develop its lead compound through preclinical testing with the goal to pursue regulatory clearance for clinical testing. Globin plans to partner with experts in globin chemistry and protein engineering through sponsored research agreements with the University of Pittsburgh to further develop their pipeline of agents for CO poisoning and other indications.